[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

iCell Gene Therapeutics has developed multiple patented technologies that fall into two broad categories: Single-chain variable fragments (scFvs) that target a specific surface marker on cancer cells (CAR targets), and _CAR EnhancementsÓ (CEs) – that can be used to enhance any CAR technology.

Its first-in-class T cell technology platform comprised of multiple scFvs that _targetÓ heterogeneous group of aggressive T cell malignancies, and corresponding CAR-modified NK cells (NK CARs), expanding the type of immune cells that can be deployed against the cancer.